Back

The real-world safety of ticagrelor among older adults (above 75 years): a pharmacovigilance study from the FDA data

1 September 2024 (18:00 - 18:40)
Organised by: Logo
Congress Presentation Part of: Cardiovascular disease in the elderly Cardiovascular Disease in the Elderly ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Tsahi Tsvi Lerman

Rabin Medical Centre, Petah Tikva (Israel)

6 More presentations in this session

Presentation thumbnail
Effect of tranexamic acid in vascular surgery- a sub-study of the POISE-3 randomized clinical trial
Doctor S. Ofori (Ontario, CA)
Abstract Slides Video
Presentation thumbnail
The long-term clinical impact of high-intensity statin therapy in older patients with acute myocardial infarction
Doctor Y. Kwon (Daegu, KR)
Abstract Slides Video
Presentation thumbnail
Validation and development of a scoring system for comprehensively evaluating arterial damage in the elderly chinese
Professor Y. Zhang (Shanghai, CN)
Abstract Slides Video
Presentation thumbnail
One- and five-year mortality according to first use of ticagrelor or clopidogrel at the acute stage of myocardial infarction in elderly patients: the FAST-MI 2015 registry
Professor N. Danchin (Paris, FR)
Abstract Slides Video
Presentation thumbnail
Frailty and anticoagulant prescription in older hospitalized patients with atrial fibrillation: a multi-centred observational study
Doctor T. Nguyen (Sydney, AU)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiovascular disease in the elderly

The Event

Event poster

ESC Congress 2024

1 September 2024 18:00 CET
You may be interested in
thumbnail
Congress Presentation
Ticagrelor vs. clopidogrel in elderly patients following acute myocardial infarction: a multicenter international analysis
thumbnail
Congress Presentation
Choosing the most effective and safest P2Y12 Inhibitor for use in >70-year-old acute coronary syndrome patients: a network meta-analysis
thumbnail
Congress Presentation
One- and five-year mortality according to first use of ticagrelor or clopidogrel at the acute stage of myocardial infarction in elderly patients: the FAST-MI 2015 registry

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources